Keep PCV2 under control from start to finish with one 2-mL dose from 3 weeks of age onward.
To have full access to all the product information on this site, registration is required.
Effective control of viremia and subclinical PCV2
- High antibody response
- MDA breakthrough
- Reduces subclinical PCV2 infections and viremia
- DOI is 22 weeks following vaccination
- Less virus, more profit